Association between activation of atypical NF-κB1 p105 signaling pathway and nuclear β-catenin accumulation in colorectal carcinoma

Molecular Carcinogenesis

Volumn 49, Issue 2, 2010, Pages 121-129

  Lauscher, Johannes C ^a   Gröne, Jörn ^a   Dullat, Sonja ^a   Hotz, Birgit ^a   Ritz, Jörg P ^a   Steinhoff, Ulrich ^b   Buhr, Heinz J ^a   Visekruna, Alexander ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^c Institute for Medical Microbiology   (Germany)

Author keywords

catenin; TrCP1; Colorectal carcinoma; CRD BP; NF B1 p105

Indexed keywords

BETA ACTIN; BETA CATENIN; BINDING PROTEIN; CODING REGION DETERMINANT BINDING PROTEIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NUCLEAR FACTOR KAPPA B1 P105; PROTEIN P105; PROTEIN P50; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; CANCER TISSUE; CELL NUCLEUS; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION;

BASE SEQUENCE; BETA CATENIN; CELL LINE, TUMOR; CELL NUCLEUS; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NF-KAPPA B P50 SUBUNIT; POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 75849130818     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20606     Document Type: Article

References (33)

1. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008;8:387-398.
2. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-A mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-116.
3. Ougolkov A, et al. Associations among beta-TrCP, an E3 ubiquitin ligase receptor, beta-catenin, and NF-kappaB in colorectal cancer. J Natl Cancer Inst 2004;96:1161-1170.
4. Noubissi FK, et al. CRD-BP mediates stabilization of betaTrCP1 and c-myc mRNA in response to beta-catenin signalling. Nature 2006;441:898-901.
5. Lin A, Karin M. NF-kappaB in cancer: A marked target. Semin Cancer Biol 2003;13:107-114.
6. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system:Atreasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
7. Sakamoto K, et al. Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res 2009;15:2248-2258.
8. Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J 2004;382:393-409.
9. Lang V, et al. betaTrCP-mediated proteolysis of NF-kappaB1 p105 requires phosphorylation of p105 serines 927 and 932. Mol Cell Biol 2003;23:402-413.
10. Heissmeyer V, Krappmann D, Hatada EN, Scheidereit C. Shared pathways of IkappaB kinase-induced SCF(betaTrCP)-mediated ubiquitination and degradation for the NF-kappaB precursor p105 and IkappaBalpha. Mol Cell Biol 2001;21: 1024-1035.
11. Sun SC, Ley SC. New insights into NF-kappaB regulation and function. Trends Immunol 2008;29:469-478.
12. Visekruna A, et al. Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest 2006;116:3195-3203.
13. Belich MP, Salmeron A, Johnston LH, Ley SC. TPL-2 kinase regulates the proteolysis of the NF-kappaB-inhibitory protein NF-kappaB1 p105. Nature 1999;397:363-368.
14. Morotti A, et al. CD7/CD56-positive acute myeloid leukemias are characterized by constitutive phosphorylation of the NFkB subunit p65 at Ser536. Leukemia 2007;21:1305-1306.
15. Toes RE, et al. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med 2001;194:1-12.
16. Groll M, Huber R. Inhibitors of the eukaryotic 20S proteasome core particle: A structural approach. Biochim Biophys Acta 2004;1695:33-44.
17. Foss GS, et al. Constitutive and interferon-gamma-induced expression of the human proteasome subunit multicatalytic endopeptidase complex-like 1. Biochim Biophys Acta 1998; 1402:17-28.
18. Heink S, et al. Tumor cell lines expressing the proteasome subunit isoform LMP7E1 exhibit immunoproteasome deficiency. Cancer Res 2006;66:649-652.
19. Wilson W III, Baldwin AS. Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. Cancer Res 2008;68: 8156-8163.
20. Greten FR, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-296.
21. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3:221-227.
22. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-436.
23. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer. Cell 2006;124:823-835.
24. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007;117: 1175-1183.
25. Lind DS, et al. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery 2001;130:363-369.
26. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: Balancing life and death-A new approach to cancer therapy. J Clin Invest 2005;115:2625-2632.
27. Elcheva I, et al. CRD-BP protects the coding region of betaTrCP1mRNA from miR-183-mediated degradation. Mol Cell 2009;35:240-246.
28. Wu G, et al. Structure of a beta-TrCP1-Skp1-beta-catenin complex: Destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol Cell 2003;11: 1445-1456.
29. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309.
30. Wang CY, Guttridge DC, Mayo MW, Baldwin AS, Jr. NFkappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999;19:5923-5929.
31. Wang CY, Cusack JC, Jr., Liu R, Baldwin AS, Jr. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999;5:412-417.
32. WangJ,An H,MayoMW,Baldwin AS, YarbroughWG.LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell 2007;12:239-251.
33. Dimitriadis E, et al. Expression of oncofetal RNAbinding protein CRD-BP/IMP1 predicts clinical outcome in colon cancer. Int. J. Cancer 2007;121:486-494.